肌少症与非酒精性脂肪性肝病存在独立相关性

赵丽琼; 李良平

doi:10.3969/j.issn.1001-5256.2019.06.044

肌少症与非酒精性脂肪性肝病存在独立相关性

DOI: 10.3969/j.issn.1001-5256.2019.06.044

1. 川北医学院
2. 四川省医学科学院四川省人民医院消化内科

详细信息

中图分类号: R575.5;R685
计量
- 文章访问数: 1052
- HTML全文浏览量: 18
- PDF下载量: 253
- 被引次数: 0
出版历程
- 收稿日期: 2018-12-26
- 出版日期: 2019-06-20

Independent association between sarcopenia and nonalcoholic fatty liver disease

Chuanbei Medical College

摘要

摘要: 非酒精性脂肪性肝病是一种可进展为肝纤维化、肝硬化及肝癌的代谢性疾病,肌少症是一种增龄相关性疾病,代谢相关因素在其发生中也发挥了重要作用,两者共享多种代谢性病理生理机制。非酒精性脂肪性肝病与肌少症之间是否具有相关性、是否互为诱因或互为疾病进展危险因素尚需进一步研究,以帮助临床更好的对两者进行预防、治疗及预后评估。就非酒精性脂肪性肝病与肌少症的独立相关性进行综述。
- 非酒精性脂肪性肝病 /
- 肌减少症 /
- 综述
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease which can progress to liver fibrosis, liver cirrhosis, and liver cancer. Sarcopenia is an age-related disease and metabolic factors play an important role in its pathogenesis. NAFLD and sarcopenia share a variety of metabolic pathophysiological mechanisms. Further studies are needed to determine whether there is an association between NAFLD and sarcopenia and whether they are predisposing factors or risk factors for disease progression for each other, in order to help with better prevention, treatment, and prognostic evaluation of the two diseases in clinical practice. This article reviews the independent association between NAFLD and sarcopenia.
- non-alcoholic fatty liver disease /
- sarcopenia /
- review

HTML全文

参考文献(33)

[1]HASHIMOTO E, TANIAI M, TOKUSHIGE K.Characteristics and diagnosis of NAFLD/NASH[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 4) :64-70.

[2]FARRELL GC, CHITTUR S, LAU GK, et al.Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:Executive summary[J].J Gastroenterol Hepatol, 2007, 22 (6) :775-777.

[3]BYRNE CD, TARGHER G.NAFLD:A multisystem disease[J].JHepatol, 2015, 62 (1) :s47-s64.

[4]MISHRA A, YOUNOSSI ZM.Epidemiology and natural history of nonalcoholic fatty liver disease[J].J Clin Exp Hepatol, 2015, 35 (3) :221-235.

[5]FAN JG, FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol, 2009, 50 (1) :204-210.

[6]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2300.

[7] BHANJI RA, NARAYANAN P, ALLEN AM, et al.Sarcopenia in hiding:The risk and consequence of underestimating muscle dysfunction in NASH[J].Hepatology, 2017, 66 (6) :2055-2065.

[8]LIOU I, KOWDLEY KV.Natural history of nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2006, 40 (Suppl) :s11.

[9]CHEN LK, LIU LK, WOO J, et al.Sarcopenia in Asia:Consensus report of the asian working group for sarcopenia[J].JAm Med Dir Assoc, 2014, 15 (2) :95-101.

[10]KIM H, HIRANO H, EDAHIRO A, et al.Sarcopenia:Prevalence and associated factors based on different suggested definitions in community welling older adults[J].Geriatr Gerontol Int, 2016, 16 (Suppl 1) :110-122.

[11]Chinese Society of Osteoporosis and Bone Mineral Research.Consensus statements on sarcopenia[J].Chin J Osteoporosis Bone Miner Res, 2016, 9 (3) :215-227. (in Chinese) 中华医学会骨质疏松和骨矿盐疾病分会.肌少症共识[J].中华骨质疏松和骨矿盐疾病杂志, 2016, 9 (3) :215-227.

[12] CRUZJENTOFT AJ, KIESSWETTER E, DREY M, et al.Nutrition, frailty, and sarcopenia[J].Aging Clin Exp Res, 2017, 29 (1) :1-6.

[13]CHEN YL.Research of the current suitation and mechanism of sarcopenia[J].Fudan Univ J Med Sci, 2016, 43 (6) :751-756. (in Chinese) 陈玲燕.肌少症的现况调查及发病机制研究进展[J].复旦学报:医学版, 2016, 43 (6) :751-756.

[14]HONG HC, HWANG SY, CHOI HY, et al.Relationship between sarcopenia and nonalcoholic fatty liver disease:The Korean Sarcopenic Obesity Study[J].Hepatology, 2014, 59 (5) :1772-1778.

[15] KOO BK, KIM D, JOO SK, et al.Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J].J Hepatol, 2017, 66 (1) :123-131.

[16]KALYANI RR, CORRIERE M, FERRUCCI L.Age-related and disease-related muscle loss:The effect of diabetes, obesity, and other diseases[J].Lancet Diabetes Endocrinol, 2014, 2 (10) :819-829.

[17] MARTIN V, GONZALEZ R, MENDOZA J, et al.Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease[J].Rev Esp Enferm Dig, 2013, 105 (7) :409-420.

[18] PEDERSEN BK, FEBBRAIO MA.Muscles, exercise and obesity:Skeletal muscle as a secretory organ[J].Nat Rev Endocrinol, 2012, 8 (8) :457-465.

[19]MILLER AM, WANG H, BERTOLA A, et al.Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice[J].Hepatology, 2011, 54 (3) :846-856.

[20]ZHANG HJ, ZHANG XF, MA ZM, et al.Irisin is inversely associated with intrahepatic triglyceride contents in obese adults[J].J Hepatology, 2013, 59 (3) :557-562.

[21] BOSTROM P, WU J, JEDRYCHOWSKI MP, et al.A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.[J].Nature, 2013, 481 (4) :463-468.

[22] HONDARES E, POSELL M, DIAZDELFIN J, et al.Peroxisome proliferator-activated receptorα (PPARα) induces PPARγcoactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat:Involvement of PRDM16[J].J Biol Chem, 2011, 286 (50) :43112.

[23]STIENSTRA R, SAUDALE F, DUVAL C, et al.Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptorαactivity[J].Hepatology, 2010, 51 (2) :511-522.

[24]MERLI M, DASARATHY S.Sarcopenia in non-alcoholic fatty liver disease:Targeting the real culprit?[J].J Hepatology, 2015, 63 (2) :309-311.

[25]GARCIA, PAUL S, CABBABE, et al.Elevated myostatin levels in patients with liver disease:A potential contributor to skeletal muscle wasting[J].Anesth Analg, 2010, 111 (3) :707-709.

[26]DASARATHY, SRINIVASAN.Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?[J].Hepatology, 2014, 60 (1) :22-25.

[27] HAN S, CHIANG JYL.Mechanism of vitamin d receptor inhibition of cholesterol 7-hydroxylase gene transcription in human hepatocytes[J].Drug Metab Dispos, 2009, 37 (3) :469-478

[28]DUNLOP TW, VAISANEN S, FRANK C, et al.The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha, 25-dihydroxyvitamin D3 and its nuclear receptor[J].J Mol Biol, 2005, 349 (2) :248-260.

[29]ELIADES M, SPYROU E, AGRAWAL N, et al.Meta-analysis:Vitamin D and non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther, 2013, 38 (3) :246-254.

[30] RIACHY R, VANDEWALLE B, CONTE JK, et al.1, 25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokineinduced apoptosis:Implication of the antiapoptotic protein A20[J].Endocrinology, 2002, 143 (12) :4809-4819.

[31] MOLINARO F, PASCHETTA E, GAMBINO R, et al.Gut Microbiota as a modulator of cardiometabolic risk:Mechanisms and therapeutic implications[J].Curr Cardiovasc Risk Rep, 2012, 6 (1) :71-79.

[32]XIA F, ZHOU BJ.Role of gut-liver axis dysfunction in pathogenesis of non-alcoholic fatty liver disease:Implications for treatment strategies[J].World Chin J Dig, 2018, 26 (24) :1439-1447. (in Chinese) 夏凡, 周本杰.肠-肝轴功能紊乱在非酒精性脂肪肝病发病机制中的作用及相关治疗策略[J].世界华人消化杂志, 2018, 26 (24) :1439-1447.

[33]SINAL CJ, TOHKIN M, MIYATA M, et al.Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J].Cell, 2000, 102 (6) :731-744.

施引文献

资源附件(0)

访问统计